CAPR vs SRPT

Capricor Therapeutics is undergoing a critical transition from clinical development to commercialization following the Q3/Q4 2025 FDA approval of CAP-1002 for Duchenne Muscular Dystrophy (DMD). This approval targets a multi-billion dollar market with high unmet needs, particularly for non-ambulatory patients, offering a substantial revenue pathway. The company benefits from regulatory exclusivity ...

Sarepta's 10x growth potential remains highly challenged by persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance ($1.2B-$1.4B from $1.86B in 2025). While recent initial Phase 1/2 siRNA data shows promise for future pipeline diversification and an sNDA for traditional approval of existing PMOs is planned, these bright...